By Patrick Wingrove Sept 7 (Reuters) - Novo Nordisk said on Monday it had halted two additional trials of its experimental cardiovascular drug ziltivekimab, further denting the Danish drugmaker's ...

Novo Nordisk A/S stopped two more trials for its experimental heart disease medicine, in a further blow to the drug’s prospects. Earlier this year Novo said ziltivekimab failed to reduce the risk of ...

Novo Nordisk (NVO) has halted two late-stage trials of its experimental heart drug ziltivekimab, adding to the drugmaker’s recent pipeline setbacks. The Danish company said on Monday that an ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

According to a report on September 7, 2026, Novo Nordisk announced that it has halted two additional clinical trials of its experimental cardiovascular drug ziltivekimab due to lack of efficacy, ...

Nearly 1 million HealthCare.gov enrollees who paid full price are getting $500 checks. See who qualifies and how to avoid scams tied to the payments. New CPSC recalls cover Amazon baby bath seats and ...

Novo Nordisk is downgraded to Hold as GLP-1 franchise strength is offset by pipeline setbacks and growth normalization. Halting of ziltivekimab cardiovascular trials weakens Novo's diversification ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Novo Nordisk halts two more ziltivekimab heart-failure trials after a data monitor found limited likelihood of success, leaving only the ARTEMIS post-MI study active. Novo Nordisk's STEP Young trial ...

On September 7, 2026, Reuters reported that Novo Nordisk A/S (NYSE:NVO) halted two additional trials of its experimental cardiovascular drug ziltivekimab, further denting the Danish drugmaker’s ...